Biogen (NASDAQ: BIIB) will, this week, present data at the 31st Congress of the European Committee for Treatment and Research in Multiple Sclerosis (ECTRIMS) in Barcelona, Spain, demonstrating the ...
The FINANCIAL — Biogen unveiled new TECFIDERA (dimethyl fumarate) research that reinforces its strong and sustained efficacy in newly diagnosed relapsing-remitting multiple sclerosis (RRMS) patients ...
The European Commission has approved dimethyl fumarate (Tecfidera, Biogen Idec) as a first-line oral treatment in relapsing-remitting multiple sclerosis (MS), the company reported today. Dimethyl ...
Verywell Health on MSN
How multiple sclerosis is treated
Medically reviewed by Brigid Dwyer, MD Key Takeaways Disease-modifying therapies slow down the progression of multiple ...
WASHINGTON (Reuters) - U.S. regulators on Wednesday approved a new multiple sclerosis drug made by Biogen Idec Inc that is widely expected to become the No. 1 oral treatment for the disease, with ...
Biogen’s contingency plan to keep Tecfidera generics at bay has fallen flat. After a U.S. appeals court in November declined to resurrect a key patent on Biogen’s multiple sclerosis (MS) blockbuster ...
Generic Tecfidera is a treatment for patients with relapsing forms of multiple sclerosis, while generic Vimpat is used as monotherapy or adjunctive therapy in patients with partial onset seizures.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback